Vectorious Medical Technologies
Oran Koren has a diverse work experience. Oran started their career at AeroScout as a Product Manager from 2012 to 2013. Following this, they worked at Nanorep as a Data Analyst in 2013. Oran then joined Yuval Eilam Educational Center as a Youth Coacher from 2013 to 2017. Oran then transitioned to IMA ISRAEL as a Medical Case Manager from 2017 to 2020. In 2020, they joined Vectorious Medical Technologies as a Scientific Data Analyst and later took on the role of Medical Affairs Manager. Additionally, Oran worked at Tel Aviv Medical Center as a Medical Doctor from 2022 to 2022.
Oran Koren completed their education in a chronological manner. They started their academic journey in 2014 at The Hebrew University of Jerusalem, where they pursued a Bachelor of Medical Sciences (B.Med.Sc) degree. This program lasted from 2014 to 2017.
After completing their bachelor's degree, Oran Koren enrolled simultaneously at Tel Aviv University in two different programs. In 2017, they began the Master of Public Health (MPH) program, which they completed in 2018. Additionally, in the same year, Oran Koren commenced their Doctor of Medicine (MD) degree at Tel Aviv University. They completed this program in 2021.
In addition to their formal education, Oran Koren acquired two additional certifications. In November 2021, they obtained the Advanced Cardiovascular Life Support Experienced Provider (ACLS) certificate from the American Heart Association. They later obtained the Medical Innovation for Physicians Course certification from The Israel Medical Association in December 2022.
This person is not in any offices
Vectorious Medical Technologies
1 followers
Vectorious Medical Technologies developed the V-LAP, the worlds first in-heart microcomputer which enables optimal treatment for heart failure patients, increasing their quality of life and life expectancy.The V-LAP sensory implant is the first digital, wireless, battery-less device that is able to communicate from deep within the body. Itmonitors the heart’s left atrium pressure (LAP) which has been proven to be the earliest, most accurate and effective predictor for heart failure deterioration.Vectorious is actively conducting clinical studies in Europe (Italy, Germany, UK and Israel) for the purpose of obtaining a CE mark. It is expected to launch a clinical study in the US in 2020.